P3 Health Partners Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Loss per Share (Tables)

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2026

Schedule of Computation of Basic and Diluted Net Loss Per Share

The following table provides the computation of basic and diluted net income (loss) per share:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
	(in thousands, except per share data)
Numerator–basic:
Net income (loss) attributable to controlling interest	$	15,621	$	(31,587)	$	24,288	$	(72,429)
Less: Cumulative preferred dividends	(15,170)		—		(24,740)		—
Net loss attributable to Class A common stockholders–basic	$	451	$	(31,587)	$	(452)	$	(72,429)
Numerator–diluted:
Net loss attributable to Class A common stockholders–basic	$	451	$	(31,587)	$	(452)	$	(72,429)
Effect of dilutive securities:
Net income (loss) attributable to Class V common stockholders	—		—		—		—
Liability-classified warrants	—		—		—		—
Net loss attributable to Class A common stockholders–diluted	$	451	$	(31,587)	$	(452)	$	(72,429)
Denominator–basic:
Weighted average Class A common shares outstanding–basic	3,399		3,268		3,541		3,265
Net loss per share attributable to Class A common stockholders–basic	$	0.13	$	(9.67)	$	(0.13)	$	(22.18)
Denominator–diluted:
Weighted average Class A common shares outstanding–basic	3,399		3,268		3,541		3,265
Weighted average effect of dilutive securities:
Equity-classified warrants	3,084		—		—		—
Non-Qualified stock options	100		—		—		—
Restricted stock units	44		—		—		—
Class V common stock	—		—		—		—
Weighted average shares outstanding–diluted	6,627		3,268		3,541		3,265
Net loss per share attributable to Class A common stockholders–diluted	$	0.07	$	(9.67)	$	(0.13)	$	(22.18)

Schedule of potential dilutive securities excluded from the computation of diluted net loss per share their effect would have been anti-dilutive

The following table presents potentially dilutive securities excluded from the

computation of diluted net income (loss) per share for the periods presented because their effect would have been anti-dilutive.


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
	(in thousands)
Stock warrants (1)	10,654	7,789	10,654	7,789
Stock options (1)	527	440	527	440
Restricted stock units (1)	78	156	78	156

Shares of Class V common stock (2)	3,246	3,919	3,246	3,919
Total	14,505	12,304	14,505	12,304

__________________

(1)Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net income (loss) per share.

(2)Shares of Class V common stock at the end of the period are considered antidilutive shares of Class A common stock under application of the if-converted method.